Paeds SAQs · genetics-dysmorphology-and-metabolism
Tuberous sclerosis complex — formative SAQs
Formative SAQs on recognising tuberous sclerosis complex from infantile spasms and hypomelanotic macules, applying the 2012 consensus diagnostic criteria, explaining the hamartin-tuberin-mTOR mechanism, building surveillance around SEGA and epilepsy, and offering everolimus for growing SEGA and refractory seizures.
On this page
Study tools
Target exams
Question 1 (10 marks)
A seven-month-old boy presents with clusters of flexor spasms and developmental regression. On examination under a Wood's lamp he has three hypomelanotic macules, and his EEG shows hypsarrhythmia. His father has a single ash-leaf patch and was "a slow learner" at school. (a) What is the most likely diagnosis and which diagnostic criteria do you apply? (b) Outline the immediate management of his seizures and the developmental surveillance plan. (c) Explain the molecular basis and the recurrence risk. [2]
Model answer
(a) The most likely diagnosis is tuberous sclerosis complex presenting as West syndrome (infantile spasms). The 2012 International Consensus criteria apply: definite TSC requires two major features, or one major plus two minor, or a pathogenic TSC1/TSC2 variant. Hypomelanotic macules are a major feature, infantile spasms strongly suggest cortical tubers (a second major feature), and I would confirm with brain MRI and molecular testing. Examining the father may reveal familial disease. [3]
(b) The immediate management is vigabatrin first-line for TSC-associated infantile spasms, started promptly because early seizure control protects the developing brain, with serial EEG to assess response and ophthalmic surveillance for visual-field toxicity. The developmental surveillance plan is a structured baseline assessment of cognition, behaviour and autism risk at diagnosis, with annual review, early intervention services, and educational support, because neurocognitive comorbidity dominates quality of life. [4] [8]
(c) TSC is an autosomal-dominant mTOR-opathy caused by loss-of-function variants in TSC1 (chromosome 9, hamartin) or TSC2 (chromosome 16, tuberin). The hamartin-tuberin complex is a GTPase-activating protein that restrains Rheb and brakes mTORC1; its loss drives uncontrolled cell growth. The recurrence risk to each child of an affected parent is 50 per cent, though expressivity varies widely. Cascade testing of the father and first-degree relatives is mandatory, and genetic counselling addresses reproductive options. [1]
References6ShowHide
- [1]Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers, 2016.PMID 27226234
- [2]Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet, 2008.PMID 18722871
- [3]Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Group. Pediatr Neurol, 2013.PMID 24053982
- [4]Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Group. Pediatr Neurol, 2013.PMID 24053983
- [6]French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis complex (EXIST-3). Lancet, 2016.PMID 27613521
- [8]de Vries P, Humphrey A, McCartney D, et al. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry, 2005.PMID 15981129